ProstaLund Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Anders Kristensson

Chief executive officer

SEK 2.3m

Total compensation

CEO salary percentage	17.2%
CEO tenure	1.1yrs
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Anders Kristensson's remuneration changed compared to ProstaLund's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-SEK 20m
Jun 30 2024	n/a	n/a	-SEK 22m
Mar 31 2024	n/a	n/a	-SEK 19m
Dec 31 2023	SEK 2m	SEK 394k	-SEK 17m

Compensation vs Market: Anders's total compensation ($USD207.53K) is below average for companies of similar size in the German market ($USD474.67K).

Compensation vs Earnings: Insufficient data to compare Anders's compensation with company performance.

CEO

Anders Kristensson (50 yo)

1.1yrs

Tenure

SEK 2,291,833

Compensation

Mr. Anders Kristensson has been the Chief Executive Officer of ProstaLund AB (publ) since October 2023. Mr. Kristensson served as the CEO of TikoMed AB. He has several years of experience from the Pharma i...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anders Kristensson	Chief Executive Officer	1.1yrs	SEK 2.29m	no data
Niclas Nystroom	Chief Financial Officer	less than a year	no data	no data
Johan Laven	Director of Sales & Marketing	less than a year	no data	no data

0.9yrs

Average Tenure

51yo

Average Age

Experienced Management: 7PL's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul de Potocki	Independent Director	1.1yrs	SEK 20.13k	no data
Marianne Ostlund	Independent Director	4.8yrs	SEK 96.60k	0.076% € 2.0k
Tomas Eriksson	Independent Director	1.1yrs	SEK 20.13k	no data
Annette Colin	Independent Director	1.5yrs	SEK 64.40k	no data
Per Langoo	Independent Chairman	1.1yrs	SEK 50.31k	no data
Tom Roonnlund	Independent Director	1.1yrs	SEK 20.13k	no data

1.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 7PL's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

ProstaLund Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

ProstaLund AB (publ), Annual General Meeting, May 05, 2022

Recent updates

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.082 loss in 3Q 2023)

High number of new directors

Second quarter 2024 earnings released: kr0.094 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Shareholder dilution

First quarter 2024 earnings released: kr0.062 loss per share (vs kr0.056 loss in 1Q 2023)

New major risk - Market cap size

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.21 loss in FY 2022)

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

Third quarter 2023 earnings released: kr0.082 loss per share (vs kr0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.072 loss in 2Q 2022)

ProstaLund AB (publ) Decides to Withdraw its 510(k) Application and Intend Instead to Submit a De Novo Application for Schelin Catheter® in the US

Prostalund AB (Publ) Announces Successfully Used At Asst Grande Ospedale Metropolitano Niguarda

First quarter 2023 earnings released: kr0.056 loss per share (vs kr0.042 loss in 1Q 2022)

Full year 2022 earnings released: kr0.21 loss per share (vs kr0.17 loss in FY 2021)

ProstaLund AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

ProstaLund Receives CE Approval Under MDR for its New Treatment Platform Coretherm® Eagle

High number of new and inexperienced directors

ProstaLund Files its 510(k) Application to the FDA for the Schelin Catheter

High number of new and inexperienced directors

Prostalund AB (Publ) Announces Coreflow® - Soft Stent - First Patient in the Uk Under Treatment

Less than half of directors are independent

Full year 2021 earnings released

ProstaLund Successfully Introduces Schelin Catheter as Tool

ProstaLund AB (publ) to Report Q1, 2022 Results on May 11, 2022

ProstaLund AB (publ), Annual General Meeting, May 05, 2022

ProstaLund AB (publ) Receives Utility Patent in China

Second quarter 2021 earnings released: kr0.066 loss per share (vs kr0.096 loss in 2Q 2020)

Prostalund Signs A Four-Year Framework Agreement with the Västra Götaland Region

New 90-day high: €0.66

Third quarter earnings released

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age